Abstract:Puerarin is a potential therapeutic agent for cardiovascular diseases. But its poor oral bioavailability restricts Its clinical application. In present study, as an evaluation of a formulation to improve the bioavailability of the drug, puerarin and its phospholipid complex were given to rats by intragastrically (i.g.) administration to compare pharmacokinetic, tissue distribution, and excretion. Serum samples were obtained at designated times after a single oral dose of 400 mg/kg puerarin or its complex. Tissue samples (heart, liver, spleen, kidney, lung, and brain), urine, and feces were collected and analyzed by a sensitive and specific high. performance liquid chromatography (HPLC) method after i.g. administration of puerarin or its phospholipid complex. Compartmental and non-compartmental analyses were applied to the serum concentration versus time data. Pharmacokinetic parameters were calculated using the 3P97 pharmacokinetic software package. An open two-compartment, first-order model was selected for pharmacokinetic modeling. The results showed that after i.g. administration of 400 mg/kg puerarin and its phospholipid complex (equivalent to 400 mg/kg of puerarin), the pharmacokinetic parameters of the two formulations were different. The serum concentrations reached peaks at 0.894 +/- 0.521 h and 0.435 +/- 0.261 h, respectively, indicating the complex was more readily absorbed in serum than puerarin. The maximum concentrations for puerarin and its complex were 1.367 +/- 0.586 mg.L-1 and 2.202 +/- 1.28 mg.L-1 and AUC were 5.779 +/- 1.662 mg.h. L-1 and 8.456 +/- 0.44 mg.h L-1, respectively, indicating a higher bioavailability for the complex. The widely distribution characteristics of puerarin and its complex in tissues post-i.g. administration was identical and in a descending order as follows: lung, kidney, liver, heart, spleen, and brain. However, the amount was different. Puerarin distribution was higher in heart, lung, and brain after administering the complex. The cumulative 72 h urinary excretion of puerarin after i.g. administration of puerarin and its complex accounted for 1.05%, 1.11% of the administered dose, respectively. The cumulative feces excretion of puerarin was 32.3% and 25.5%. To sum up, oral administration of puerarin phospholipid complex modified the pharmacokinetics and tissue distribution of puerarin and it could be an effective oral formulation for puerarin.

Bioavailability of Puerarin-Phospholipid Solid Dispersion in Rats

Pharmacokinetic, Tissue Distribution, and Excretion of Puerarin and Puerarin-Phospholipid Complex in Rats

Determination of puerarin in rat cortex by high-performance liquid chromatography after intravenous administration of Puerariae flavonoids.

Comparative Pharmacokinetic Profiles of Puerarin in Rat Plasma by UHPLC-MS/MS after Oral Administration of Pueraria lobata Extract and Pure Puerarin

Improvement in Solubility and Bioavailability of Puerarin by Mechanochemical Preparation

Preparation and Evaluation of Puerarin-loaded PLGA Nanoparticles for Improving Oral Bioavailability in SD Rats

Determination of Puerarin in Biological Samples and Its Application to A Pharmacokinetic Study by Flow-Injection Chemiluminescence

LC-MS/MS Method for the Determination of a New Puerarin Derivative and Its Application in Pharmacokinetic Studies in Rats

Study on Pharmacokinetics and Relative Bioavailability of Puerarin Proliposomes

Determination of puerarin in rat liver microsomes by LC-MS and its pharmacokinetics

Studies on the Absorption Kinetics of Different Purities of Puerarin in Rats' Intestine

Simultaneous Quantification of Puerarin and Daidzein in Rat Plasma by High-Performance Liquid Chromatography with Post-Column Modification and Fluorescence Detection

Determination of Huperzine A in Human Plasma by LC-MS/MS and Its Application to Relative Bioavailability of Huperzine A Tablets

An Ultra High Performance Liquid Chromatography with Tandem Mass Spectrometry Method for Simultaneous Determination of Thirteen Components Extracted from Radix Puerariae in Rat Plasma and Tissues: Application to Pharmacokinetic and Tissue Distribution Study.

Comparative Pharmacokinetic Study of Paeoniflorin after Oral Administration of Decoction of Radix Paeoniae Rubra and Radix Paeoniae Alba in Rats

Enhanced Oral Bioavailability of Acetylpuerarin by Poly(lactide-Co-glycolide) Nanoparticles Optimized Using Uniform Design Combined with Response Surface Methodology

HPLC Method for the Determination and Pharmacokinetic Studies on Puerarin in Cerebral Ischemia Reperfusion Rat Plasma after Intravenous Administration of Puerariae Radix Isoflavone.

[Distribution of Puerarin Contained in Zige Freeze-Dried Powder Injection in Rat Liver and Kidney].

[Pharmacokinetics, pharmacodynamics, and tissue distribution of oral co-loaded puerarin/daidzein mixed micelles in rats]

HPLC determination of polydatin in rat biological matrices: application to pharmacokinetic studies.

Formulation and Pharmacokinetics Evaluation of Puerarin Nanocrystals for Intravenous Delivery